The escalating burden of heart disease in younger women
New projections from the American Heart Association suggest that cardiovascular risk factors and clinical cardiovascular disease in women will increase substantially through 2050.
The projected rise in cardiometabolic risk factors
Cardiovascular disease (CVD) and stroke remain the leading causes of morbidity and mortality among women in the United States. A 2026 Scientific Statement from the American Heart Association provides updated projections of cardiovascular risk factors and clinical disease through 2050, based on historical trends from NHANES and MEPS data combined with US Census population estimates.
The projections suggest a substantial increase in major cardiometabolic risk factors over the next three decades. The prevalence of hypertension among adult women is estimated to rise from 48.6% in 2020 to 59.1% in 2050. Diabetes is projected to increase from 14.9% to 25.3%, and obesity from 43.9% to 61.2%.
In contrast, hypercholesterolemia is projected to decline from 42.1% to 22.3%, reflecting continued improvements in lipid screening and treatment.
However, this apparent success in lipid management does not translate into an overall decline in projected cardiovascular disease prevalence. The simultaneous rise in obesity and diabetes suggests a shifting cardiometabolic landscape in which residual risk persists despite effective LDL-lowering strategies. In other words, pharmacological advances in lipid control may mitigate atherosclerotic risk, yet they are unlikely to offset the broader metabolic burden driven by excess adiposity and dysglycaemia. This epidemiological pattern underscores the limits of a prevention strategy centred primarily on lipid-lowering therapy.
Health behaviors show mixed trajectories: suboptimal diet, inadequate physical activity and smoking are projected to decline modestly, whereas inadequate sleep is expected to increase slightly over time.
While improvements in smoking and cholesterol management may partly mitigate atherosclerotic risk, the projected parallel rise in obesity and diabetes suggests a shift toward a broader cardiometabolic burden, with potential downstream effects on heart failure and stroke incidence.
Importantly, the projections are driven not only by changes in prevalence but also by demographic dynamics. Population aging, combined with growth in specific age strata, amplifies the absolute number of women living with cardiometabolic conditions, even when relative increases appear moderate.
Increasing prevalence of clinical cardiovascular disease
The projected rise in risk factors translates into a growing burden of clinical cardiovascular disease. The prevalence of coronary heart disease in women is expected to increase from 6.85% to 8.21% by 2050. Heart failure is projected to rise from 2.45% to 3.60%, stroke from 4.14% to 6.74%, and atrial fibrillation from 1.58% to 2.31%. Overall, the combined prevalence of total cardiovascular disease and stroke is projected to increase from 10.7% in 2020 to 14.4% in 2050.
Beyond prevalence, the statement highlights condition-specific patterns with important epidemiological implications. Women are disproportionately affected by heart failure with preserved ejection fraction, and stroke remains a major contributor to disability and long-term care needs among older women. The projected increase in atrial fibrillation further suggests a potential rise in cardioembolic stroke and chronic anticoagulation needs.
Although older women continue to carry the highest absolute burden, relative increases are particularly pronounced among younger women. In women aged 20-44 years, projected increases in hypertension, diabetes and stroke prevalence are especially concerning, suggesting that adverse cardiometabolic trajectories are emerging earlier in life.
Projections among girls and adolescents reinforce this life-course perspective. While hypertension and diabetes in girls are expected to remain relatively stable, obesity is projected to increase markedly, from 19.6% in 2020 to 32.0% in 2050.
These early trends may contribute to the expanding cardiovascular burden in adult women and indicate that prevention strategies targeting childhood obesity could have long-term cardiovascular impact.
Disparities and implications beyond the United States
The projected burden is not evenly distributed across demographic groups. Black women have the highest baseline and projected prevalence of hypertension, diabetes and obesity, and Black as well as American Indian/Alaska Native or multiracial women show particularly high projected prevalence of total cardiovascular disease. Hispanic and Asian women demonstrate substantial projected growth in several risk factors, even when baseline prevalence is lower.
These findings underscore the persistent role of demographic and social determinants in shaping cardiovascular risk trajectories.
Although these projections are based on US data, the epidemiological signals are relevant for Europe and Germany. Cardiovascular diseases remain the leading cause of death among women in Germany, accounting for roughly 40% of all female deaths according to federal statistics. Recent national health monitoring reports indicate persistent prevalence of hypertension, obesity and diabetes in adult women, with concerning patterns in middle-aged groups. In the context of population ageing and increasing cardiometabolic risk across high-income countries, the projected US trajectories may serve as an early warning for European health systems.
- Joynt Maddox KE, Reynolds HR, Adedinsewo D, Bushnell C, DeVon HA, Gooding HC, Howard VJ, Mauricio R, Miller EC, Sharma G, Waken RJ; American Heart Association Women’s Health Science Committee of the Council on Clinical Cardiology and Stroke Council; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; and Council on Peripheral Vascular Disease. Forecasting the Burden of Cardiovascular Disease and Stroke in Women in the United States Through 2050: A Scientific Statement From the American Heart Association. Circulation. 2026 Feb 25. doi: 10.1161/CIR.0000000000001406. Epub ahead of print. PMID: 41738095.
- Robert Koch Institute (RKI). Herz-Kreislauf-Erkrankungen. Gesundheitsberichterstattung des Bundes. Berlin: RKI; 2025.
- Robert Koch Institute (RKI). Koronare Herzkrankheit: Sterblichkeit in Deutschland 2023. Gesundheitsberichterstattung des Bundes. Berlin: RKI; 2025.
- Statistisches Bundesamt (Destatis). Todesursachenstatistik 2024. Wiesbaden: Destatis; 2024.